LUCID CAPITAL MARKETS Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $30

Benzinga Newsdesk www.benzinga.com Neutral 50.0%

Neg 0% Neu 50% Pos 0%

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $30.